



CORRECTION

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Vera Gorbunova¹, J. Thaddeus Beck², Ralf-Dieter Hofheinz³, Pilar Garcia-Alfonso⁴, Marina Nechaeva⁵, Antonio Cubillo Gracian⁶, Laszlo Mangel⁷, Elena Elez Fernandez⁸, Dustin A. Deming⁹, Ramesh K. Ramanathan¹⁰, Alison H. Torres¹¹, Danielle Sullivan¹¹, Yan Luo¹¹ and Jordan D. Berlin¹²

British Journal of Cancer (2019) 121:429–430; <https://doi.org/10.1038/s41416-019-0528-0>

Correction to: *British Journal of Cancer* (2019) **120**, 183–189; <https://doi.org/10.1038/s41416-018-0343-z>; published online 11 December 2018

The original version of this article contained an error in Fig. 1a. The number of patients at risk listed in the Veliparib arm of Fig. 1a should have read “65” instead of “35”. The correct figure is below.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; ²Highlands Oncology, Rogers/Fayetteville, AR, USA; ³Interdisciplinary Tumor Center, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany; ⁴Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁵Arkhangelsk Clinical Oncology Center, Arkhangelsk, Russia; ⁶Centro Integral Oncológico Clara Campal Hospital Universitario Madrid Sanchinarro, Madrid, Spain, and Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain; ⁷Pecsi Tudományegyetem Klinikai Központ, Onkoterapias Intezet, Pécs, Hungary; ⁸Vall d'Hebron University Hospital, Barcelona, Spain; ⁹University of Wisconsin, Madison, WI, USA; ¹⁰Mayo Clinic, Scottsdale, AZ, USA; ¹¹AbbVie Inc., North Chicago, IL, USA and ¹²Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Correspondence: Jordan D. Berlin (jordan.berlin@vumc.org)

Published online: 26 July 2019




Fig. 1 a Progression-free survival at final analysis and **b** overall survival at final analysis. CI confidence interval, PBO placebo + FOLFIRI ± bevacizumab, VEL veliparib + FOLFIRI ± bevacizumab